Diaceutics Opens Asian Hub to Capitalize on Growing Market

Diaceutics, the diagnostics data analytics and implementation services company, today announces that it is opening a new regional hub in Asia. With more than 10% of the companys annual revenues now coming from the Asian market, the announcement represents Diaceutics official move into the continent, supported by the Singapore Economic Development Board (EDB).

Diaceutics estimates that there are currently more than 300 targeted oncology drugs in late stage development across the major Asian markets. From its Asian HQ, Diaceutics will support the launch of “ and access to “ precision therapies in China, Japan, Hong Kong, South Korea, Thailand and Taiwan.

Diaceutics currently works with 166 laboratories across Asia. In order to maximize patient impact, it will expand its Asian laboratory network, allowing it to gather patient testing data and work with pharmaceutical companies and local manufacturers to improve testing accuracy and turnaround times. As a result, more people in Asia will be able to access the treatment that is right for them; giving them the best possible chance of recovery.

Diaceutics Asia is building an initial team of six “ consisting of lab directors, data scientists and sales personnel “ working to reinforce its presence and patient impact in Asia. With offices also in the US, UK and Ireland, this latest expansion will help Diaceutics in its international growth plans.

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

Damian Thornton, COO, Diaceutics, said: Diaceutics is on a mission to improve patient outcomes worldwide through better testing. With more than half of the worlds population residing in Asia, this is a natural step for us. Singapore provides the ideal hub from which to ramp up our work in Asia and the EDB was instrumental in helping us to establish here. We are excited to have a very skilled team of scientists and business people, who share the companys vision of helping to improve patient outcomes through better testing.

We expect our presence in Asia will be buoyed by recent activity in the Chinese precision medicine market. The country is making a concerted effort to provide those who get sick access to the latest and most effective treatments. That means rapidly approving ground-breaking new drugs. This is making it an attractive market for pharmaceutical companies to launch new therapies and as more targeted treatments become available, efficient biomarker testing will be crucial to getting those drugs to the right people. That is where we believe we will make a difference “ not only in China but also throughout the rest of Asia.

Ms. Ho Weng Si, Director, Healthcare, Singapore EDB, said: Diaceutics decision to establish its Asia Hub in Singapore reflects a growing need for more holistic pharmaceutical and diagnostic solutions to enable personalized medicine in Asia. We welcome Diaceutics addition to Singapores growing healthcare ecosystem.

– Ends –

About Diaceutics Diaceutics is transforming an industry model by enabling pharmaceutical companies to accelerate their market penetration and achieve a better return on new therapies by helping them to revolutionise their patient testing. It does this by providing insights generated from its real-time testing data from its worldwide laboratory network, helping Pharma to understand and leverage the diagnostic landscape and deploy initiatives that aid patient diagnosis. The company has experience of more than 300 precision medicine projects and works with 31 of the worlds top 35 pharmaceutical companies. The company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com

About the Singapore Economic Development Board The Singapore Economic Development Board (EDB), a government agency under the Ministry of Trade and Industry, is responsible for strategies that enhance Singapores position as a global centre for business, innovation, and talent. We undertake investment promotion and industry development, and work with international businesses, both foreign and local, by providing information, connection to partners and access to government incentives for their investments. Our mission is to create sustainable economic growth, with vibrant business and good job opportunities for Singapore. For more information on EDB, visit www.edb.gov.sg

Helen Morrogh
Comit
Tel: +353 1 215 7675
Mob: +353 85 781
4755
www.comit.ie